Clients

Oramed Pharmaceuticals Inc.

Company Snapshot: Oramed Pharmaceuticals Inc.

ORMP
Last Change Volume High Low

Company Overview

Oramed Pharmaceuticals is a technology pioneer in the field of oral delivery solutions for drugs currently delivered via injection. Established in 2006, Oramed’s Protein Oral Delivery (POD™) technology is based on over 30 years of research by top scientists at Jerusalem’s Hadassah Medical Center. Oramed is seeking to revolutionize the treatment of diabetes through its proprietary flagship product, an orally ingestible insulin capsule (ORMD-0801). The Company completed multiple Phase II clinical trials under an Investigational New Drug application with the U.S. Food and Drug Administration. In addition, Oramed is developing an oral GLP-1 analog capsule (ORMD-0901).

Client News

  1. May 24 2022 Oramed Granted U.S. Combination Therapy Patent for Oral GLP-1 & Insulin for the Treatment of Diabetes
  2. May 18 2022 Oramed to Present at H.C. Wainwright Global Investment Conference
  3. May 3 2022 Oramed Completes Patient Enrollment in Pivotal Phase 3 Oral Insulin Study ORA-D-013-1
  4. Apr 5 2022 Oramed Granted NASH Patent in Europe